A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia
In the register
The register attaches this trial to CKD-843 (Chong Kun Dang Pharmaceutical), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 3
- Sponsor
- Chong Kun Dang Pharmaceutical
- Participants (registry)
- 288
- Start
- April 2025
- Primary completion
- September 2027 (planned)
- Study completion
- June 2028 (planned)
- Last registry update
- September 2026
- Countries
- South Korea
Conditions studied: Androgenetic Alopecia
Interventions: CKD-843 dose#1, CKD-843 dose#2, Placebo of CKD-843 dose, Dutasteride Capsules, Placebo of Dutasteride Capsule
Other trials of CKD-843
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.